Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 294

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 294
---
., a wholly owned subsidiary of Scilex Holding Company, with whom it shares voting and investment control, and 6,250,000 shares held by Scilex Bio, Inc., a majority owned subsidiary of Scilex Holding Company, with whom it shares voting and investment control. |

| (6) | Consists of (i) 554,849 shares of Common Stock purchased from Scilex Holding Company and (ii) 11,945,151 shares of Common Stock purchased from Scilex, Inc. Biconomy’s address is 1st Floor, Ellen Skelton Building, 3076 Sir Francis Drake’s Highway, Road Town, Tortola, VG1110, British Virgin Islands. |

191

SELLING SECURITYHOLDERS This prospectus relates to the offer and sale from time to time by:

| 1. | the Selling Stockholders of up to an aggregate of 203,737,349 Resale Shares, consisting of: (i) up to 2,072,500 Sponsor Shares; (ii) up to 188,554,849 Scilex Shares; (iii) up to 510,000 Private Warrant Shares issuable pursuant to Private Warrants; (iv) up to 100,000 Underwriter Shares; (v) up to 12,500,000 Biconomy Resale Shares; and |

| 2. | the Selling Warrantholders, of up to 510,000 Private Warrants. |

A description of our relationships with certain of the Selling Securityholders and their affiliates is set forth in “ Certain Relationships and Related Person Transactions.” We cannot advise you as to whether the Selling Securityholders will in fact sell any or all of such shares of Common Stock or Warrants. In particular, the Selling Securityholders identified below may have sold, transferred or otherwise disposed of all or a portion of their securities after the date on which they provided us with information regarding their securities in transactions exempt from registration under the Securities Act. Information about the Selling Securityholders may change over time. Any changed information will be set forth in a prospectus supplement or amendments to the registration statement of which this prospectus is a part, if and when required. Any prospectus supplement or amendments to the registration statement may add, update, substitute, or change the information contained in this prospectus, including the identity of each Selling Securityholder and the number of shares registered on its behalf. A Selling Securityholder may sell or otherwise transfer all, some or none